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BIOETHICS IN BLOOD AND MARROW TRANSPLANTATION (BMT): AD-
VANCED CARE PLANNING AND ADVANCED DIRECTIVE (AD)
Neumann, J.L., Smith, M., Causton, C., Hosing, C. University of Texas
M.D. Anderson Cancer Center, Houston, TX.
The risk for nonsurvival after BMT may vary depending on the
type of transplantation and the individual patient’s risk factors (ie,
comorbid conditions, infection history, refractory nature of the
disease). An important part of the informed consent process and
preparing the patient and family for possible complications pre-
BMT includes communicating the relevance of these risks factors
to overall outcome. Communicating risks while maintaining a
sense of hope may be difﬁcult.
Based on Joint Commission for Accreditation of Hospitals Or-
ganization (JCAHO) requirements, patients are asked if they have
advance directives at the time of admission and given information
if they do not have the proper documents. Despite these measures,
however, the percentage of inpatients nationally with AD remains
low (approximately 30%). As part of a quality improvement pro-
cess, AD information was collected on 100 BMT inpatients. Survey
results indicated that 39% of patients said they had AD, 29%
supplied a copy before admission, and only 20% had a copy
available in their inpatient chart. Some patients (19%) had both a
living will and medical power of attorney.
In an effort to increase advanced care planning discussion and
advanced directive completion, the Bioethics in BMT task force
initiated several activities, including participating in an admission
class for BMT patients, providing for viewing of a video on ad-
vanced directives, preparing a document titled “Hope for the Best,
Prepare for the Worst”, and providing BMT attendings with
information about patients’ living will choices pretreatment. Fol-
low-up survey results and information about these activities will be
presented and discussed.
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LATE EFFECTS OF STEM CELL TRANSPLANTATION COMPARED TO
CHEMOTHERAPY/RADIATION REPORTED BY SURVIVORS IN A WEB-
BASED SURVEY
Barnes, Y.J.1, Hauff, M.2, Shenoy, S.2 1St. Louis Children’s Hospital,
St. Louis, MO; 2Washington University School of Medicine, St. Louis,
MO.
Background. The intensity and duration of chemotherapy
and/or radiation delivered for the treatment of cancer dictates
toxicities in survivors. Age at diagnosis, tumor, location, and sur-
gical intervention are additional factors that inﬂuence complica-
tions. Further intervention, such as stem cell transplantation
(SCT), can compound residual toxicities. The aim of this study was
to analyze toxicities perceived by survivors after SCT compared
with survivors (without SCT) using a web-based electronic survey
as a tool. Methods. A project undertaken by the Late Effects and
School/Societal Reintegration Program at our institution included
a summary of the main side effects encountered post therapy on
our website: http://webbugs.wustl.edu. The goal was to dissemi-
nate basic information, raise medical awareness, list resources, and
encourage follow-up. An anonymous survey invited visitors to
report their treatment and describe residual late effects, if any.
Data were compiled from surveys of survivors with and without
SCT. Survey questions included diagnosis, age, treatment, dura-
tion posttherapy, medical and psychosocial complications, and ad-
equacy of medical care, as perceived by the respondent. Results.
Twenty-two SCT survivors responded. Responders were parents
(19), patients (1), and friends (2). Median age at diagnosis was 2–5
years (range, 0–17 years). Sixteen had completed therapy 5 years
earlier, 3 were 5–10 years posttherapy, and 3 were unknown. There
were 7 males and 9 females (and 6 unknown). Diagnoses included
leukemia in 7 patients, solid tumors in 12, lymphoma in 2, and
other in 2. Conditioning for SCT included radiation in 13 (59%)
and no radiation in 4 (18%). Overall, 63.6% (14 of 22) reported
adequate medical support. Table 1 compares the percentage of side
effects in survivors from the 2 groups. Conclusions. SCT recipi-
ents were 1.2 times more likely to experience late effects than
non-SCT patients. Growth failure, delayed puberty, infertility, and
cosmetic, dental, and endocrine problems were more frequent after
SCT. Radiation and chemotherapy survivors described learning
disabilities with increased frequency. Interestingly, both groups
had rare patients (2 in each group) who perceived no side effects.
The high incidence of late effects in survivors range from medical
issues to psychosocial problems and underscores the need for
dedicated “late effects” multidisciplinary clinics to recognize these
problems. Successful cancer therapy should be combined with
formal programs that address these issues.
Toxicities SCT (%) No SCT (%)
Growth failure 54 12
Pubertal/Infertility 68 29
Endocrine dysfunction 59 45
Learning disabilities/seizures 32 54
Depression 36 33
Organ dysfunction
(eye, heart, lung) 59 58
Chronic pain 27 29
Cosmetic/physical handicap 59 41
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PARENTS ROOMING-IN DURING THEIR CHILD’S HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Vachon, M.-F., Richer, J., Dalle, J.-H., Duval, M., Champagne, M.A.
Hoˆpital Sainte-Justine, Montreal, QC, Canada.
Background.HSCT in children is a stressful experience for their
parents. At the inception of our program in 1993, we decided to
not permit parental rooming-in. We thought that parents could
thus beneﬁt from a rest period, maintain their family system, and
conserve energy for the long hospitalization expected for their
child. Some parents questioned our policy, because throughout our
hospital, with the exception of the ICU and HSCT units, children
can beneﬁt from the presence of their parents. In contrast to our
position, most transplantation centers in North America allow
parental rooming-in during a child’s HSCT. A literature review
was inconclusive. We therefore surveyed 120 families whose child
received HSCT at our center, to evaluate the effect of our policy
on the parental level of stress, the child’s anxiety, and/or the impact
on the nursing team. Methods. Families who had a child recipient
of an HSCT between 1993 and 2002 were surveyed by mail. One
of the parents answered the questionnaire, which evaluated the
degree of information on the rationale for the policy, parent and
child reaction, current perception on the policy, current choice
that parents would make, and suggestions on possible rooming-in.
Results. A total of 42 questionnaires (35%) were returned. Re-
sponses were provided mainly by the mothers (54%). At the time
of HSCT, 14 families (34%) returned home daily (median dis-
tance, 32.5 km), whereas 28 (67%) stayed at the hospitality suite in
the immediate vicinity of the hospital. Before the HSCT, 20 (48%)
stayed overnight with their child during hospitalization; for 7
(17%), this was a ﬁrst hospitalization. Thirteen (32%) initially
agreed with the program policy. Twenty-six (62%) of the surveyed
families stated they would have stayed the night with their child at
the time of HSCT if permitted; however, after HSCT, 16 (53%) of
the families who would have or may have stayed overnight now
indicated that they would not stay. The main reason given was to
beneﬁt from a greater period of rest. None of the families that did
not consider staying at night reconsidered their choice in retro-
spect. Six families (14%) noted that their child never grew accus-
tomed to their absence at night. Conclusion. Rooming-in during
HSCT may be an option for some families. We are currently
studying the beneﬁts and disadvantages of rooming-in for the
child, the parents, and the nursing team during this period of
intensive care.
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